Trial intelligence / Profile preview

ODYSSEY

2024-515462-14-00Phase 4Authorised

Sponsor: IQVIA
Start: Nov 2024
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Countries: 7

Overview

Phase 4, open-label trial of gadobenate dimeglumine, gadobutrol, gadoterate meglumine, gadoteridol and gadoxetate disodium (3 arms), sponsored by IQVIA. Primary endpoints: Change from baseline to Year 5 in composite motor function z score and Change from baseline to Year 5 in composite cognitive function z score. Planned start Nov 2024; status: authorised.

Drugs

gadobenate dimegluminegadobutrolgadoterate megluminegadoteridolgadoxetate disodium

Beyond the preview

Go deeper on 2024-515462-14-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-515462-14-00.